Delivery Order SPE2DB25D2203-SPE2DB25FPSDJ
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injectors, with a contract ceiling value of $15,256.35 and an ultimate completion date of July 21, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound is a branded GLP-1 receptor agonist...
- The Defense Logistics Agency awarded a $6,970.68 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injectors. The contract is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, and will be fulfilled at the contractor's Conshohocken, Pennsylvania facility. This award represents a non-set-aside competitive procurement, demonstrating AmerisourceBergen's continued capability to meet federal pharmaceutical...
- The Defense Logistics Agency awarded a $2,348.46 firm fixed-price delivery order to AmerisourceBergen Drug Corp for supply of Zepbound 5 mg/0.5 ml pen injections, with performance completion targeted for August 4, 2025. The contract, awarded August 1, 2025, represents a non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The performance location is AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Zepbound 5 mg/0.5 ml pens with a ceiling value of $2,726.72. This is a firm fixed-price delivery order with an ultimate completion date of July 30, 2025, and represents a non-set-aside competitive award. The product will be delivered to the company's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a $4,043.29 delivery order to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 mL pen injectors on July 30, 2025, with a completion date of July 31, 2025. This competitively awarded, firm fixed-price contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX. The product will be delivered to AmerisourceBergen's Corporate Office location in...
- The Defense Logistics Agency awarded a delivery order valued at $9,320.22 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injectors on July 23, 2025, with an ultimate completion date of July 24, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist indicated for weight management...
- The Defense Logistics Agency awarded a delivery order valued at $3,188.64 to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 ml pen injections on July 22, 2025, with an ultimate completion date of July 23, 2025. This is a firm fixed price, non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through...
- The Defense Logistics Agency awarded a $2,287.74 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 2.5 mg/0.5 mL pen injectors on July 25, 2025, with an ultimate completion date of July 28, 2025. This delivery order was competitively awarded with no set-aside designation and is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication used for weight management, reflecting the Defense...
- The Defense Logistics Agency awarded a $2,287.74 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 ml pen injection on July 30, 2025, with an ultimate completion date of July 31, 2025. This non-competitive delivery order represents a single-line item pharmaceutical procurement fulfilled from AmerisourceBergen's existing contract vehicle. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. Zepbound is a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injections with a ceiling value of $1,586.80. This is a firm fixed-price delivery order with an ultimate completion date of July 31, 2025, and represents a non-set-aside competitive award. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound is a diabetes and weight management medication,...
- SPE2DB25D2203Indefinite Delivery Contract
- SPE2DB25D2203-SPE2DB25FPSDJDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $5,138.94 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 ml pen injectors on July 29, 2025, with an ultimate completion date of July 30, 2025. This competitive award, with no set-aside designation, utilizes firm fixed pricing and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound, a GLP-1 receptor agonist medication used for weight management, represents part of the company's broader pharmaceutical supply portfolio to federal medical systems. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a $999.99 billion prime contract vehicle extending through December 2026 that provides comprehensive global pharmaceutical and medical supply support to military healthcare programs. The parent IDC enables AmerisourceBergen to fulfill diverse pharmaceutical requirements across multiple therapeutic domains for the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. The company's continued selection for such orders reflects its demonstrated capability to meet federal procurement standards through competitive procurement processes and its role as a critical pharmaceutical distributor within the defense supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.1k | 7/29/25 |